© Reuters. The spread of coronavirus disease (COVID-19) in Dublin
(Reuters) – Oxford University announced Tuesday that it had suspended a small UK study testing the COVID-19 vaccine developed with AstraZeneca (NASDAQ 🙂 Plc in children and adolescents, pending further data on it rare blood clotting problems waiting for adults who have received the shot.
The trial interruption is the latest blow to the vaccine, which was once hailed as a milestone in the fight against the pandemic after several countries restricted its use amid reports of medical problems following vaccination.
There were no safety concerns in the pediatric study, Oxford University said, adding that it would await guidance from the UK drug watchdog before any further vaccinations.
The university announced in February that it would be accepting 300 UK-based volunteers, ages 6-17, as part of this study.
The European Medicines Agency (EMA) is currently reviewing reports of an extremely rare cerebral blood clot known as cerebral venous sinus thrombosis (CVST) following the AstraZeneca shots and is expected to announce its results on Wednesday or Thursday.
A senior EMA official said there is a clear link between the vaccine and CVST, although the direct cause of the clot is still unknown.
The World Health Organization, which is working with other regulators to closely examine the latest data on AstraZeneca's vaccine, said Tuesday there will be no reason to change its assessment that the benefits of the shot outweigh the risks.
Spats with governments across Europe about production, supply, possible side effects and the benefits of the vaccine have been haunting the Anglo-Swedish drug manufacturer for months.
Anthony Fauci, the leading U.S. infectious disease doctor, told Reuters last week that the U.S. may not need AstraZeneca's vaccine even if it gets regulatory approval.
Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media or any person involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.